Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

Gabriele Schilling, Michael L. Coonfield, Christopher A. Ross, David R. Borchelt

Research output: Contribution to journalArticle

Abstract

Huntington's disease (HD) is a progressive inherited neurodegenerative disorder, for which there is no effective therapy. The CARE-HD study, recently published, evaluated the ability of a combination of coenzyme Q10 (CoQ10) and remacemide hydrochloride (R) to ameliorate symptoms, which might arise from glutamate-mediated excitotoxicity and abnormalities in mitochondrial energy production. In this study, we examined the efficacy of CoQ10/R therapy on ameliorating the motor dysfunction and premature death of HD-N171-82Q transgenic mice. Motor performance, measured on the Rotarod, was specifically but transiently improved beginning 3 weeks after initiating the CoQ10/R therapy. Survival, however was not prolonged. Our findings suggest that further study of CoQ10/R in mouse models is warranted to investigate whether this therapeutic approach can ameliorate the symptoms of HD in early stages of the disease.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
JournalNeuroscience Letters
Volume315
Issue number3
DOIs
StatePublished - Nov 27 2001

Keywords

  • Coenzyme Q10
  • Drug trial
  • HD-N171-82Q transgenic mice
  • Huntington's disease
  • Intranuclear inclusions
  • Remacemide hydrochloride

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model'. Together they form a unique fingerprint.

  • Cite this